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Background: Technetium-99m methoxyisobutylisonitrile (Tc MIBI) is a substrate with the same uptake kinetics as
doxorubicin. Multidrug resistance (MDR) is a mechanism that impedes chemotherapy of non-small cell lung cancer
(NSCLC). We examined the effect of radiation exposure on MDR in NSCLC and the synergy between an MDR
modulator, GG918, and radiation, using 99mTc MIBI in vitro and doxorubicin in vivo.
Methods: In vitro NSCLC cells (H1299) were exposed to radiation (3-, 6-, and 9-Gy-irradiated groups) alongside a
not-irradiated (0 Gy) group. Technetium-99 metastable methoxyisobutylisonitrile (99mTc MIBI) was administered
to cell suspensions at 48 h after irradiation. Cell radioactivity was measured, and Cin/Cout ratios were calculated
and compared. NSCLC cells were also subcutaneously transplanted into the left thigh of nude mice, which were
subsequently raised for 2 weeks. Two groups of mice were used: mice exposed to irradiation (9-Gy-irradiated)
and those that were not (not-irradiated). Doxorubicin was administered through the caudal vein at 48 h after the
irradiation. Using an in vivo imaging system, intratumoural photon counts were measured. To determine the
synergy between the MDR modulator and 3- or 6-Gy irradiation, the final GG918 concentration was determined:
0.1 μM (N-H, 3-H, and 6-H groups), 0.001 μM (N-L, 3-L, and 6-L groups), and 0 μM (N-0, 3-0, and 6-0 groups).
Cin/Cout ratios were calculated and compared among the groups.
Results: Cin/Cout after 6- or 9-Gy irradiation was significantly higher than that of the not-irradiated group (0 Gy).
In vivo, fluorescence photon counts were significantly higher in the tumours of 9-Gy-irradiated mice, up to
270 min after administration of doxorubicin, as compared to the not-irradiated mice. The Cin/Cout ratio in the N-H,
3-H, and 6-H groups was significantly higher than that in the N-0, 3-0, and 6-0 groups. There was no significant
difference between Cin/Cout in the N-L group and that of the N-0 group. However, the Cin/Cout ratio in the 3-L
and 6-L groups was significantly higher than that in the 3-0 and 6-0 groups.
Conclusions: Irradiation decreased MDR in NSCLC cells. In combination with a low-dose MDR modulator, GG918,
MDR transport function was synergistically reduced 48 h post-irradiation.
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Non-small cell lung cancer (NSCLC) accounts for more
than 80% of diagnosed lung cancer cases and is often de-
tected at an advanced stage, rendering it extremely difficult
to treat with current therapeutic regimes. Lung cancer that
is detected in the advanced stage may be treated with
molecular-targeted drugs; however, it is commonly treated* Correspondence: kanno@ka2.so-net.ne.jp
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in any medium, provided the original work is pwith chemoradiotherapy [1]. For chemotherapy, the current
practice is to deliver several anticancer drugs with different
mechanisms of action, thereby reducing the dose of each
drug required, thus, decreasing the occurrence of side ef-
fects, as well as benefitting from synergistic tumour reduc-
tion effects. Thus, combination therapy is commonly used
as a treatment regimen for lung cancer.
On the other hand, radiotherapy depends on the sensitiv-
ity of specific tumour cells to radiation. The effectiveness of
hyperfractionated radiation therapy, i.e., irradiation overn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tumour cell cycle, has also been investigated. The goal of
established chemoradiotherapy is to achieve tumour vol-
ume reduction, whereas novel combinations of chemother-
apy and radiotherapy aim to reduce both tumour volume
as well as the occurrence of side effects. However, combin-
ation therapies are often discontinued because of the side
effects of both irradiation and anticancer drugs.
Furthermore, there is a growing concern that treatment
efficacy may not be sufficient because of multidrug resist-
ance (MDR) [2]. The overexpression of P-glycoprotein
(Pgp) and breast cancer-resistant protein (BCRP) in the
membranes of tumour cells plays a major role in the devel-
opment of MDR [3,4]. Cancer cells bearing the MDR
phenotype are capable of eliminating anticancer drugs,
such as cisplatin or doxorubicin, by using Pgp and BCRP as
an efflux channel protein, thereby diminishing their chemo-
therapeutic actions [4].
99mTc MIBI, used for myocardial perfusion scintigraphy
and imaging of the parathyroid gland, is a substrate of Pgp
and is known to have similar tumour cell kinetics to cis-
platin and doxorubicin [5]. In addition, MDR modulators
(e.g., verapamil, GG918, PSC833, and cyclosporin A) re-
duce the transporter function of Pgp and BCRP [6,7]. These
modulators bind to Pgp and BCRP, thereby preventing
these membrane-bound protein channels from transporting
anticancer drugs out of tumour cells. However, to achieve
this effect, a high dose of such modulators must be admin-
istered [8,9]. Consequently, these modulators have not been
used in combination with any chemoradiotherapeutic or
chemotherapeutic regimen, due to concerns regarding their
toxicity.
In this study, NSCLC cells (in vitro) and tumours
(in vivo) with an MDR phenotype were exposed to vary-
ing doses of radiation, as well as 99mTc MIBI and doxo-
rubicin, respectively, to investigate the effect of radiation
on MDR and MDR modulators.
Methods
Ethical consideration
In this study, the institutional and national guide for the
care and use of laboratory animals was followed and the
protocols used were approved by the Institutional Re-
view Board of Kansai Medical University.
Reagents
99mTc MIBI (Cardiolite; Fujifilm RI Pharma., Co., Ltd.,
Tokyo, Japan) and doxorubicin (Adriamycin; Kyowa Hakko
Kirin Co., Ltd., Tokyo, Japan) were used as tracers. A stock
solution of 99mTc MIBI was prepared by mixing 10 MBq
of 99mTc MIBI with 2 mL of saline solution; this solu-
tion was then used in the in vitro and in vivo experi-
ments [10,11]. A stock solution of doxorubicin was
prepared by mixing 1 mg of doxorubicin with 1 mL ofsaline solution. This solution was then used in the in vivo
experiment. A stock solution of MDR modulator was pre-
pared from an acridone carboxamide derivative, GG918,
(N-{4-(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquino-
linyl)-ethyl)-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-
acridine carboxamide; Elacridar; MedChem Express, LLC,
Monmouth Junction, NJ, USA) [7,12].
Cell culture and xenografts
In vivo and in vitro experiments were conducted using
NSCLC cells (H1299), transfected with a wild-type P53-
encoding gene, which was supplied by Hideki Matsumoto,
Ph.D., Oncology, Biomedical Imaging Research Centre,
Fukui University, Japan [13]. ICR nude mice (Crlj: CD1-
Foxn1nu) were used for xenografting (Charles River La-
boratories, Wilmington, MA, USA) [14].
For the in vitro study, H1299 cells were cultured as
monolayers in Dulbecco’s alpha-MEM medium (D-
MEM; Sigma-Aldrich, St. Louis, MO, USA) supple-
mented with 10% (v/v) foetal bovine serum (Equitech-
Bio, Kerrville, TX, USA), 50 μg/mL streptomycin, and
200 μg/mL geneticin and were incubated at 37°C in
95% air and 5% CO2. Prior to culturing, the cells were
subjected to 3-, 6-, and 9-Gy (irradiated groups) gamma
irradiation (Gammacell 40 Exactor, Nordion Inter-
national, Ottawa, Canada). Cells from the irradiated
groups and the not-irradiated group were cultured for
48 h as previously described. H1299 cells were trypsi-
nized and centrifuged, and each cell suspension was di-
luted to a density of 0.5 to 1.0 × 106 cells/mL [10,11].
For the in vivo study, H1299 cells were cultured as
previously described, trypsinized, and then centrifuged
four times with Dulbecco’s phosphate-buffered saline
(D-PBS; Gibco; Invitrogen Co., Ltd, Carlsbad, CA, USA)
at 4°C, after which cells were resuspended in D-PBS. We
transplanted 5.0 × 107 cells into the left thighs of mice,
which were then raised for 2 weeks to allow tumour for-
mation [12,14,15]. After 2 weeks, the tumour volume
(mm3) was calculated; tumours ≥20 mm3 were used for
further study. Xenografts were subjected to 9-Gy gamma
irradiation (Gammacell 40 Exactor, Nordion Inter-
national, Ottawa, Canada), incubated for 48 h, and then
used for experimentation.
Expression of transporters in H1299 cells
H1299 cells were smeared onto silane-coated slides (No.
5136, MUTO, Co.. Ltd., Tokyo, Japan) and fixed in 100%
ethanol. The cells were incubated in 0.3% H2O2 in 0.05 M
D-PBS for 15 min at room temperature and then washed
three times with 0.05 M PBS for 3 min. Afterwards, the
cells were blocked with 5% skim milk (v/v) and 0.15%
H2O2 (v/v) in de-ionized water for 20 min at room
temperature. Primary antibodies against Pgp and BCRP
were then added and allowed to react with the cells
Figure 1 Region of interest (ROI) setting of the xenograft. The
ROIs were set to the contralateral site of the affected area, using the
same size as the tumour site in the thigh.
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using a 1/500 dilution of anti-BCRP/ABCG2 antibody
(ab72788, Abcam, Co., Ltd., Cambridge, MA, USA) or anti-
Pgp monoclonal antibody (4E3.16, #517308, Calbiochem,
Co., Ltd., San Diego, CA, USA). Isotype control was con-
ducted using mouse IgG1 (ICIGG1; ab91353, Abcam, Co.,
Ltd., Cambridge, MA, USA) and mouse control IgG2a
[MOPC-173] - ChIP Grade (ab18413).
After washing with 0.05 M PBS, the cells were incu-
bated in 0.05 M D-PBS containing peroxidase-labelled
polymer conjugated to goat anti-mouse immunoglobulin
for 30 min. After washing with 0.05 M D-PBS, the slides
were stained with 3-3′-diaminobenzidine-4HCl (DAB)
for 1 min. Finally, the slides were washed in 0.05 M PBS
and stained with 50% Mayer’s haematoxylin on the cover
slide for 1 min [15].
To assess the quality of Pgp and BCRP expression,
Allred scores were used; the proportion score (PS); the
percentage of cells that were stained by immunocyto-
chemistry (on a scale of 0 to 5) and the intensity score
(IS); the intensity of the staining (on a scale of 0 to 3),
for a total possible score of 8. Total scores were compared
between the 9-Gy-irradiated and not-irradiated tumour
cells [16].
Cellular accumulation of 99mTc MIBI
To determine cellular transport activity, cell suspensions
(7.0 mL) were thoroughly mixed and incubated in a 37°C
water bath. Approximately 100 μL of 99mTc MIBI was
then added to the cell suspensions. To evaluate intra-
cellular accumulation, 300 μL aliquots were collected in
duplicate 1, 15, 30, 45, and 60 min after 99mTc MIBI ad-
ministration. The aliquots were transferred to 1.5-mL
microcentrifuge tubes containing 1.0 mL of ice-cold sa-
line and centrifuged at 14,000 rpm for 2 min; the super-
natants were removed, and the cells washed gently with
0.5 mL of ice-cold saline solution. Radioactivity in the
cell pellets was measured at 90 to 190 keV using a
gamma-counter (WIZARD™ 3” Model 1480 Automatic
Gamma Counter, PerkinElmer Life Sciences, Co., Ltd.,
Waltham, MA, USA). The accumulation ratio (Cin/Cout)
was calculated as the ratio of intracellular to extracellular
radioactivity in an equal volume of supernatant medium,
using an independent measurement of cell volume as
described previously [11]. The time course of 99mTc MIBI
accumulation was measured in the not-irradiated group
and in the 3-, 6-, and 9-Gy-irradiated groups [10,11].
Accumulation of doxorubicin in tumours
Doxorubicin (stock solution, 100 μL) was administered
via the caudal vein to the not-irradiated mice and the
9-Gy-irradiated mice at 48 h after irradiation for in vivo
fluorescence imaging [17]. Fluorescence (photons·s−1·cm−2)
was measured, to evaluate the accumulation of doxorubicin(Figure 1), in the xenografted tumour thigh region and in
the bilaterally symmetrical control thigh region using an
in vivo imaging system (IVIS 200, Caliper Life Science Inc.,
Hopkinton, MA, USA) equipped with air-cooled argon la-
sers (emission at 488 nm) and a 575-nm band pass filter
[11,15]. Changes in doxorubicin accumulation in the ROIs
were detected by fluorescence imaging over time. Washout
rate was calculated using the following equation:
Doxorubicin washout rate %ð Þ ¼ Fluorescence in the tumourðf
at 10 min after doxorubicin administration−Fluorescence at 60;
120; or 270 min after doxorubicin administrationÞ=Fluorescence
at 10 min after doxorubicin administrationg  100:
Effects of GG918 on 99mTc MIBI accumulation in cells after
irradiation
H1299 cells were subjected to 3- and 6-Gy gamma ir-
radiation. Irradiated cells and not-irradiated cells were
separately cultured in tissue culture flasks. H1299 cells
were trypsinized and centrifuged to prepare 7 mL of
single-cell suspensions in fresh media with a density of
0.5 to 1.0 × 106 cells/mL. GG918 was added to a final con-
centration of 0, 0.001, and 0.1 μM to the irradiated and
not-irradiated cell suspensions at 5 min before addition of
99mTc MIBI. In the not-irradiated group, the cell suspen-
sions to which 0, 0.001, and 0.1 μM of GG918 were added
were defined as the N-0 group, the N-L group, and the
Figure 2 The immunocytochemistrical expression of Pgp and BCRP. The immunocytochemistrical expression of Pgp and BCRP was positive,
the proportion score (PS) 5/5 + the intensity score (IS) 3/3 = total score 8/8, localizing these proteins to the cell membrane of the not-irradiated
tumour cells.
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groups, the cells to which 0, 0.001, and 0.1 μM of
GG918 were added were defined as the 3-0 group or 6-0
group, the 3-L group or 6-L group, and the 3-H group or
6-H group, respectively.Figure 3 The immunocytochemistrical expression of Pgp and BCRP in tu
expression of Pgp and BCRP was positive, PS 5/5 + IS 3/3 = total score 8/8, loca
cells. There was no difference in the expression of Pgp and BCRP between cellRadioactivity was measured using a gamma counter
30 min after the administration of 99mTc MIBI, and the
99mTc MIBI cellular accumulation ratio (Cin/Cout) was
calculated. The accumulation of 99mTc MIBI was com-
pared between the N-H, N-L, and N-0 groups and bothmour cells, at 48 h after 9-Gy irradiation. The immunocytochemistrical
lizing these proteins to the cell membrane of the 9-Gy-irradiated tumour
s before and after 9-Gy irradiation.
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Statistical analysis
The samples used in the in vitro experiments were mea-
sured in duplicate. The data were expressed as the mean ±
standard error (SE). The Kruskal-Wallis test and a post hoc
multiple comparison test were conducted using Fisher’s
protected least significant difference (PLSD) test. A P value
less than 0.05 was considered statistically significant.
Results
Characterization of transporters in H1299 cells
Immunodetection of Pgp and BCRP was positive, with
these proteins localized in the membranes of H1299 cells
(Figures 2 and 3). In the not-irradiated cells shown in
Figure 2, the expression of Pgp and BCRP were as follows:
PS 5 + IS 3 = 8. There was no change after 9-Gy irradi-
ation, followed by 48 h of culturing, as shown for the
cells in Figure 3, with both Pgp and BCRP being PS 5 + IS
3 = 8.Figure 4 99mTc MIBI accumulation study. Compared to the not-irradiated
in the 6-Gy group and the 9-Gy group.Cellular accumulation of 99mTc MIBI after irradiation
The cellular accumulation of 99mTc MIBI is shown in
Figure 4. Cin/Cout increased after approximately 30 min.
Cin/Cout in all groups reached a plateau within 60 min.
Cin/Cout in the 6-Gy-irradiated and 9-Gy-irradiated groups
was higher than that in the 3-Gy-irradiated group and the
not-irradiated group (P < 0.05). There was no significant
difference observed between the 3-Gy-irradiated group
and the not-irradiated group.
Doxorubicin accumulation in tumours after irradiation
Figure 5 represents a fluorescence image of a xenograft.
The tumour site of the 9-Gy-irradiated mouse exhibited
fluorescence, indicating an accumulation of doxorubicin,
whereas the tumour site of the not-irradiated mouse did
not exhibit significant fluorescence, indicating little or
no doxorubicin accumulation.
Figure 6 shows the fluorescence photon count as a func-
tion of time. Compared to the tumour site of the not-
irradiated mouse, the tumour site of the 9-Gy-irradiated
mouse showed significantly higher accumulation, withgroup, the cellular uptake of 99mTc MIBI increased statistically significantly
Figure 5 Doxorubicin fluorescence imaging. The upper section indicates an image of the 9-Gy-irradiated mouse. The lower section indicates
an image of the not-irradiated mouse. The tumour site of the 9-Gy-irradiated mouse showed sufficient accumulation of doxorubicin in the upper
section, whereas that of the not-irradiated mouse showed no significant accumulation of doxorubicin.
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administration.
The washout rate for the tumour site of the 9-Gy-
irradiated mouse was 4.3% ± 0.5%, whereas that of the
tumour site of the not-irradiated mouse was 12.3% ± 2.2%
by 30 min after doxorubicin administration. Approximately
120 min after doxorubicin administration, approaching the
midpoint of photo counting, the washout rate of the
tumour site of the 9-Gy-irradiated mouse was 3.4% ± 0.3%,
whereas that of the tumour site of the not-irradiated
mouse was 23.4% ± 3.5%. At 270 min after administration,
i.e., at the endpoint of photon counting, the washout rate
of the tumour site of the 9-Gy-irradiated mouse was
15.0% ± 2.3%, whereas that of the tumour site of thenot-irradiated mouse was 45.8% ± 1.8%. Therefore, the
washout rate of the tumour site of the 9-Gy-irradiated
mouse was significantly lower, over the 270 min of
measurement after administration, compared to that of
the not-irradiated mouse, indicating that significantly
more doxorubicin remained within the tumour.
Cellular accumulation of 99mTc MIBI in the presence of
GG918 after irradiation
Figure 7 presents the accumulation of 99mTc MIBI in
cultured NSCLC cells to which the MDR modulator
GG918 had been added. Although the 99mTc MIBI accu-
mulation in the N-H group was significantly higher than
that in the N-0 and N-L groups, no significant differences
Figure 6 Time-photon curve of doxorubicin in the 9-Gy-irradiated mouse and not-irradiated mouse. The accumulation of doxorubicin in
the tumour site of the 9-Gy-irradiated mouse was around 4 to 4.5 (108 photons·s−1·cm−3) for approximately 120 min after administration and then
washed out gradually. On the other hand, the accumulation of doxorubicin in the tumour site of the not-irradiated mouse was around 2 to 2.5
(108 photons·s−1·cm−3) at 30 min after administration, which was significantly lower than that in the 9-Gy-irradiated mouse. The site was subjected
to washout at 30 min after administration, although the degree of washout was significantly greater than that observed in the 9-Gy-irradiated mouse.
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group were observed. 99mTc MIBI accumulation in the 3-
H group was significantly higher than that in the 3-0 and
3-L groups. 99mTc MIBI accumulation in the 3-L group
was significantly higher than that in the 3-0 group. The
6-0, 6-L, and 6-H groups also showed the same signifi-
cant tendency as the 3-0, 3-L, and 3-H groups. 99mTc
MIBI accumulation was enhanced by irradiation, even
in the presence of a low dose of GG918.
Discussion
Pgp and BCRP are known to actively transport antican-
cer drugs, such as doxorubicin and cisplatin, out of cells;
however, their actual mechanism of action remains elu-
sive. This mechanism of active elimination of anticancer
drugs is one key factor that gives rise to MDR. Reducing
MDR transport function has been an important ongoing
challenge in cancer treatment and has thus been exten-
sively investigated [3,8,9]. This study revealed enhanced
uptake of 99mTc MIBI in NSCLC cells in vitro after 6- and
9-Gy irradiation, and an extended intracellular doxorubi-
cin residence time in in vivo xenografted NSCLC tumours
at 48 h after 9-Gy irradiation, although there was no dif-
ference in the expression of Pgp and BCRP between cells
before and after 9-Gy irradiation immunocytochemically.Thereby suggesting that MDR transport function may
have been reduced in both in vitro and in vivo experi-
ments. In clinical lung cancer treatment, however, 6 Gy,
9 Gy, or higher doses of irradiation per radiotherapy do
not constitute an established treatment method, due to a
lack of evidence that reduces tumour volume. However,
studies have shown that a reduction in MDR transport
function can be achieved using low-dose fractionated radi-
ation therapy (LDFRT) [18,19]. A previous study has dem-
onstrated a reduction of MDR transport function in highly
radiosensitive oral squamous cell carcinoma cell lines
by 48 or 72 h after irradiation [18]. The administration
of chemoradiotherapy, in combination with cisplatin, to
NSCLC cells has also resulted in improved therapeutic
efficacy of LDFRT, as compared to single-fraction therapy
[19]. These reports suggested that the choice of irradiation
method (e.g., LDFRT) and the time elapsed after irradi-
ation, rather than the total radiation dose during treat-
ment, may lead to a reduction in MDR transport function.
The present study found no significant reduction in MDR
transport function at 24 h after 6- and 9-Gy irradiation;
in vitro 99mTc MIBI accumulation and in vivo doxorubicin
uptake in xenografted tumours were both found to be
non-significant (data not shown). However, at 48 h after
irradiation, the in vitro accumulation of 99mTc MIBI and
Figure 7 Various concentrations of GG918 administered and accumulation of 99mTc MIBI in cells measured at 30 min after administration.
The Cin/Cout at 30 min after the addition of
99mTc MIBI is shown in the graph. The Cin/Cout of the N-H, 3-H, and 6-H groups was significantly higher than
that of the N-0, 3-0, and 6-0 groups. In addition, the Cin/Cout in the N-H, 3-H, and 6-H groups was significantly higher than those in the N-L, 3-L, and
6-L groups. On the other hand, although there was no significant difference in the values between the N-0 group and the N-L group, those of the 3-L
and 6-L groups were significantly higher than those of the 3-0 and 6-0 groups.
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were both significantly higher than in the not-irradiated
groups. These results indicate the potential clinical utility
of 6 Gy or higher doses of single-fraction radiation, which
is contrary to the findings of previous studies. Although
no report has demonstrated the efficacy of single-fraction
radiation, we suggest that one possible reason for this was
that the experiments were conducted at less than 48 h
after irradiation.
Pgp and BCRP are localized in the cell membranes of
normal cells, such as those of the intestines, lungs, prox-
imal tubules of the kidney, and in capillary endothelial
cells of the blood-brain barrier [20]. These transporter
proteins are also present in the cells of lung and breast
tumours. 99mTc MIBI has long been used for imaging of
myocardial perfusion and parathyroid gland uptake and
is known as a substrate of Pgp [5,10]. 99mTc MIBI thus
exhibits the same kinetics in vivo as doxorubicin and cis-
platin. Knowledge of the kinetics of 99mTc MIBI and
doxorubicin may help in planning treatment strategies
for cancer. Doxorubicin accumulation in tumour cells
can be monitored through fluorescence imaging if the
tumour is located on the skin surface. Consequently, it
is generally difficult to image doxorubicin as a tracer in
humans, and thus, no previous studies have reported this
specific imaging approach. Previous studies have shownthat 99mTc MIBI is a suitable radiotracer for imaging and
can be used to image tumours [11,12]. Several reports
using this approach have noted that the use of high-dose
low-efficacy chemotherapy, with the associated serious
side effects, can be reduced [5,21,22]. In addition, other
reports have found that 99mTc MIBI scintigraphy can be
used for chemotherapy prognosis in lung cancer, wherein
MRP, Pgp, or BCRP are expressed [23,24]. The present
study also supported these findings and has shown that
99mTc MIBI and doxorubicin appear to have similar
kinetics.
In this study, we also investigated chemical modulators
that reduce MDR transport function as well as the effect
of irradiation on MDR transport function. Previous
in vitro and in vivo studies have demonstrated that the
mechanisms of action of the MDR modulators verapamil,
GG918, cyclosporin A, and PSC833 depend largely on the
dose of the compounds used [3,25]. GG918, a selective
MDR modulator of Pgp and BCRP, inhibits the function
of these transporters and increases 99mTc MIBI cellular ac-
cumulation [10]. A phase I clinical trial using GG918 re-
vealed problems relating to clinical safety and efficacy of
this agent [9]. It has also been reported that a concentra-
tion of 0.01 μM GG918 is ineffective as a modulator and
that MDR transport function may be reduced with high
doses (0.1 μM or 0.2 μM); these concentrations, however,
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MIBI uptake in in vitro NSCLC cells was high after
addition of 0.1 μM GG918 in the absence of irradiation.
The 99mTc MIBI uptake in NSCLC cells in vitro did not
increase after addition of 0.001 μM GG918; however, after
3- or 6-Gy irradiation, the cellular uptake of 99mTc MIBI
significantly increased even after addition of only
0.001 μM GG918. These results suggest that the com-
bination of irradiation and a low-dose MDR modulator
may synergistically reduce MDR transport function.
Conclusions
The NSCLC cell line H1299/wtp53 showed a reduction
in MDR transport function after irradiation at a dose of
6 Gy or higher. The combination of a low-dose (3 and
6 Gy) irradiation and a low-dose MDR modulator, GG918,
resulted in a synergistic effect that reduced MDR trans-
port function.
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